No improvement in PFS was reported from the addition of everolimus, and although there was a numerical benefit of 7 months in the sub-group of ER-negative patients, it did not reach statistical significance [ 108 ].
2
—
—
The sentences
The study met its primary endpoint, demonstrating a highly significant improvement in median progression-free survival (PFS) as well as overall response rate (ORR) and OS, as summarised in Table 1 [ 3 , 9 ].